公司資料
MeiraGTx 股價、新聞與催化劑
- 股票代碼:
- MGTX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United Kingdom with U
股票表現
13.77 USD (+1.85%)
收盤價
最後更新: 2026年8月17日
856M USD
市值
股價為何變動
As of Aug 17, 2026, MGTX closed up 1.85% at $13.77. No new same-company headline was identified in the current news window.
公司概覽
Genetic Medicines Company
MeiraGTx develops and manufactures gene therapies for inherited retinal disease, salivary-gland disorders, and other conditions. Its vertically integrated model spans vector design, clinical development, and commercial manufacturing.
Bota-Vec
Botaretigene sparoparvovec is an AAV gene therapy for X-linked retinitis pigmentosa caused by RPGR mutations. MeiraGTx acquired global rights after completion of the Phase 3 LUMEOS study.
AAV2-hAQP1
AAV2-hAQP1 delivers the aquaporin-1 water-channel gene to salivary glands as a treatment for radiation-induced xerostomia. The program has received FDA Breakthrough Therapy designation.
Riboswitch Platform
MeiraGTx's Riboswitch technology is designed to regulate therapeutic-protein production with an oral small molecule after gene delivery. Initial programs include metabolic disease and neuropathic pain.
Manufacturing Infrastructure
The company operates gene-therapy manufacturing and quality-control facilities intended to support regulatory filings and potential commercial launches.
未來催化劑
- Global regulatory filings for bota-vec in X-linked retinitis pigmentosa during 2026.
- Potential commercial launch of bota-vec in 2027, subject to approval.
- Potential BLA submission for AAV2-hAQP1 in radiation-induced xerostomia in mid-2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。